Leica Microsystems Inc.
$942.6K 487 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
NS Pharma, Inc.
NS Pharma, Inc. reported $942,067.28 across General Payments, Research, and Ownership to 369 physicians and teaching hospitals across 546 transactions.
- $942.1K Above-median payer
- All-tracks total
- 546 Above-median volume
- Transactions
- 369 Above-median reach
- Recipients
- −$10.4K
- General Payments vs PY2023
NS Pharma, Inc. reported $942,067.28 across all CMS Open Payments tracks (General + Research + Ownership) to 369 physicians and teaching hospitals in Program Year 2024 - ranking #633 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $103,068.73, averaging $2.6K per recipient.
How NS Pharma, Inc.'s $942.1K all-tracks total breaks down
NS Pharma, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
27/100
Total payments
F
19/100
Transaction volume
F
14/100
Physician reach
F
13/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ns-pharma-inc NS Pharma, Inc.
$942.1K · #633/1,925 · 0.0% industry · PY2024
- TOT $942.1K
- RANK #633
- SHARE 0.0%
- TXN 546
- RCP 369
- CAT 5
- GEN $103.1K
- ΔGEN −$10.4K
- TOP1 36.3%
- PY 2024
Volume peers
Nearest volume peer: Leica Microsystems Inc. ($942.6K)
NS Pharma, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
NS Pharma, Inc.'s CMS-reported General Payments decreased by $10.4K (−9.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NS PHARMA, INC.PY2023: NS PHARMA, INC.PY2024: NS Pharma, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $113,462.93
- PY2024
- $103,068.73
What the Data Shows for NS Pharma, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For NS Pharma, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Honoraria" at $39.1K, accounting for 37.9% of this company's General Payments and 26 transactions.
General Payment Breakdown by Type
"Honoraria" leads NS Pharma, Inc.'s 5-category general-payment breakdown at $39.1K, 37.9% of the reported total.
NS Pharma, Inc. reports 5 general-payment categories - the top three are Honoraria (37.9%), Consulting Fee (18.9%), and Travel and Lodging (17.7%). The remaining 2 categories make up 25.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How NS Pharma, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $39.1K | 26 | 37.9% |
| Consulting Fee | $19.4K | 3 | 18.9% |
| Travel and Lodging | $18.3K | 34 | 17.7% |
| Food and Beverage | $13.8K | 301 | 13.4% |
| Grant | $12.5K | 5 | 12.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $76,521.60 (74.2%) of $103,068.73 in this company's General Payments records across 225 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for NS Pharma, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Kan Hor
$37,402.44 across 48 reported transactions
- 2
Peter Merkel
$17,187.50 across 2 reported transactions
- 3
John Jefferies
$8,437.88 across 11 reported transactions
- 4
Mathula Thangarajh
$7,587.51 across 12 reported transactions
- 5
Michelle Figueroa
$5,906.27 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
NS Pharma, Inc.'s spend rank (#633 of 1,925, top 33% by spend) and concentration rank (#788 of 1,838, top 43% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Arrow International, Inc. : $376.6K total payments, HHI 1833
- Current Health Inc. : $10.2K total payments, HHI 1822
- Lsi Solutions Inc : $274.8K total payments, HHI 1813
- Photocure Inc : $179.4K total payments, HHI 1810
- LeMaitre Vascular, Inc. : $311.5K total payments, HHI 1805
- RMC Orthopedic & Surgical, Inc. : $13.5K total payments, HHI 1800
- NS Pharma, Inc. (this company) : $103.1K total payments, HHI 1796
- Avid Radiopharmaceuticals, Inc. : $8.1K total payments, HHI 1793
- Applied Medical Technology Inc : $176.9K total payments, HHI 1791
- Ignite Orthopedics, LLC : $705.4K total payments, HHI 1790
- BioPro, Inc. : $101.9K total payments, HHI 1788
- Lazarus 3D : $1.2K total payments, HHI 1788
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as NS Pharma, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about NS Pharma, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with NS Pharma, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Vascular Technology, Inc.
$943.2K 50 recipients
Compare payment profiles
OrganOx Ltd
$944.6K 100 recipients
Compare payment profiles
Heron Therapeutics, Inc.
$945.0K 4,695 recipients
Compare payment profiles
Consortium of Independent Immunology Clinics, LLC
$938.8K 91 recipients
Compare payment profiles
Carl Zeiss Meditec, Inc.
$938.6K 737 recipients
Compare payment profiles
Put this to use
NS Pharma, Inc. ranks #633 of 1,925 by all-tracks total payments, led by "Honoraria".
- See where NS Pharma, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just NS Pharma, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.